Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05450627
  4. Details
NCT05450627 Clinical Trial

Registry of Pancreatic Exocrine Insufficiency.

Exocrine Pancreatic Insufficiency Clinical Trial

Official title:
Development of a Registry of Patients With Pancreatic Exocrine Insufficiency of Different Etiologies

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05450627
Other study ID # PEI-01-2021
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2021
Est. completion date December 31, 2023

Study information
Verified date July 2022
Source Hospital Clinico Universitario de Santiago
Contact J. Enrique Dominguez-Munoz, Prof, MD, PhD
Phone -34 981 951 364
Email juan.enrique.dominguez.munoz@sergas.es
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

A prospective, cross-sectional, observational study has been designed with the aim of the study is to evaluate the diagnosis and management of patients with pancreatic exocrine insufficiency secondary to different pancreatic diseases and conditions in clinical practice. A registry has been develop to include patients older than 18 years diagnosed with pancreatic exocrine insufficiency, sho are willing to participate in the study and sign the informed consent. Registry includes demographics, toxic habits,pharmacological therapies, underlying disease that causes pancreatic exocrine insufficiency.

Recruitment information / eligibility
Status Recruiting
Enrollment 1000
Est. completion date December 31, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients older than 18 years diagnosed with PEI secondary to pancreatic diseases, pancreatectomy, or gastrectomy. - Willingness to participate in the study. Exclusion Criteria: - Patients with pancreatic diseases without PEI. - Pregnancy - Known allergy to oral pancreatic enzymes - Any condition avoiding adequate clinical management of PEI. - Patients who are not willing to participate in the study.

Study Design

Related Conditions & MeSH terms

  • Exocrine Pancreatic Insufficiency

Intervention

Drug:
• Pancreatic Enzyme
Registry of pancreatic enzyme therapy prescribed to included patients

Locations
Country Name City State
Spain Hospital Clinico Universitario de Santiago Santiago de Compostela A Coruña

Sponsors (1)
Lead Sponsor Collaborator
Hospital Clinico Universitario de Santiago

Country where clinical trial is conducted

Spain, 

Outcome
Type Measure Description Time frame Safety issue
Primary Dose of oral pancreatic enzymes Dose required for symptoms relief and normalization of the nutritional status Six months
See also
  Status Clinical Trial Phase
Completed NCT02823964 - EASY: Extended Access to Sollpura Over Years Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Completed NCT01427725 - Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Completed NCT05082051 - Oral CDX-7108 in Healthy Adults and EPI Subjects Phase 1
Completed NCT03236038 - Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
Completed NCT03407534 - Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating
Completed NCT02598128 - Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) N/A
Completed NCT00559364 - Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Phase 3
Completed NCT00408317 - Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) Phase 3
Recruiting NCT04548778 - BÜHLMANN fPELA in the Diagnosis of Exocrine Pancreatic Insufficiency
Completed NCT00449878 - Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00297167 - Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00981214 - Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Recruiting NCT05480241 - Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy N/A
Recruiting NCT05261997 - Endotherapy for Painless Chronic Pancreatitis N/A
Completed NCT02370537 - A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Phase 2
Completed NCT00559052 - An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) Phase 2
Recruiting NCT04112836 - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Completed NCT06278272 - AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients